[1]何文婷,翟云兰,张洪亮.液体活检在肿瘤监测管理中的应用[J].医学信息,2019,(19):29-31.[doi:10.3969/j.issn.1006-1959.2019.19.010]
 HE Wen-ting,ZHAI Yun-lan,ZHANG Hong-liang.Application of Liquid Biopsy in Tumor Monitoring and Management[J].Medical Information,2019,(19):29-31.[doi:10.3969/j.issn.1006-1959.2019.19.010]
点击复制

液体活检在肿瘤监测管理中的应用()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年19期
页码:
29-31
栏目:
综述
出版日期:
2019-10-01

文章信息/Info

Title:
Application of Liquid Biopsy in Tumor Monitoring and Management
文章编号:
1006-1959(2019)19-0029-03
作者:
何文婷1翟云兰2张洪亮1
(1.新疆维吾尔自治区中医医院肿瘤二科,新疆 乌鲁木齐 830000;2.北京吉因加科技有限公司,北京 102200)
Author(s):
HE Wen-ting1ZHAI Yun-lan2ZHANG Hong-liang1
(1.Department of tumor,Subject Two,Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine,Urumqi 830000,Xinjiang,China;2.Beijing Jiyinjia Technology Co.,Ltd.,Beijing 102200,China)
关键词:
液体活检肿瘤ctDNA液体监测
Keywords:
Liquid biopsyTumorctDNAFluid monitoring
分类号:
R730.43
DOI:
10.3969/j.issn.1006-1959.2019.19.010
文献标志码:
A
摘要:
目前临床在诊疗过程中,无活检组织样本的情况下,常规使用液体活检检测肿瘤敏感靶点以寻找敏感靶向药。而最新研究中液体活检计算的肿瘤突变负荷(bTMB)可以对PD-1/L1抑制剂进行疗效预测;同时越来越多的研究发现液体活检可以通过对肿瘤分子负荷进行检测分析,用于肿瘤的预后评估,微小残留病灶监测,以及肿瘤的克隆进化分析,这使得液体活检有望在肿瘤诊疗过程中辅助临床进行更全面的监测管理,本文就此做一综述。
Abstract:
At present, in the clinical diagnosis and treatment process, without biopsy tissue samples, routine use of liquid biopsy to detect tumor-sensitive targets to find sensitive targeted drugs. The tumor mutation load (bTMB) calculated by liquid biopsy in the latest study can predict the efficacy of PD-1/L1 inhibitors. At the same time, more and more studies have found that liquid biopsy can be used for tumor analysis by analyzing tumor molecular load. Prognostic assessment, micro-residual lesion monitoring, and clonal evolution analysis of tumors make liquid biopsy promising for more comprehensive monitoring and management during tumor diagnosis and treatment. This article reviews this issue.

参考文献/References:

[1]Clark JW,Longo DL.Recent progress in systemic treatment for lung cancer[J].Curr Opin Pulm Med,2018,24(4):355-366. [2]Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454. [3]Calabuig Farinas S,Jantus Lewintre E,Herreros Pomares A,et al.Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win[J].Transl Lung Cancer Res,2016,5(5):466-482. [4]Sacher AG,Paweletz C,Dahlberg SE,et al.Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer[J].JAMA Oncol,2016,2(8):1014-1022. [5]Wang Z,Cheng Y,An T,et al.Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma(BENEFIT):a phase 2,single-arm,multicentre clinical trial[J].Lancet Respir Med,2018,6(9):681-690. [6]Zhang X,Liang Z,Chen Y,et al.JCES 01.25 Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC[J].Journal of Thoracic Oncology,2017,12(11):S1739. [7]Wang Z,Lu B,Liu G,et al.P3.01-106 Real-world data to evaluate the clinical benefit of NGS for directing lung adenocarcinoma treatment[J].Journal of Thoracic Oncology,2018,13(10):S906-S907. [8]Yarchoan M,Hopkins A,Jaffee EM.Tumor Mutational Burden and Response Rate to PD-1 Inhibition[J]. N Engl J Med,2017, 377(25):2500-2501. [9]Sharabi A,Kim SS,Kato S,et al.Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy(SBRT)in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center[J].The Oncologist,2017,22(6):631-637. [10]Schumacher TN,Schreiber RD.Neoantigens in cancer immunotherapy[J].Science,2015,348(6230):69-74. [11]Rizvi NA,Hellmann MD.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128. [12]Gandara DR,Paul SM.Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J].Nat Med,2018,24(9):1441-1448. [13]Büttner R,Longshore JW,López-Ríos F,et al.Implementing TMB measurement in clinical practice: considerations on assay requirements[J].ESMO Open,2019(4):e000442. [14]Lee JH,Long GV,Menzies AM,et al.Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies[J].JAMA Oncol,2018,4(5):717-721. [15]Abbosh C,Birkbak NJ,Wilson GA,et al.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J].Nature,2017,545(7655):446-451. [16]Nong J,Gong Y, Guan Y,et al.Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer[J].Nat Commun,2019,10(1):552. [17]Raja R,Kuziora M,Brohawn PZ,et al.Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab[J].Clin Cancer Res,2018,24(24):6212-6222. [18]Goldberg SB,Narayan A,Kole AJ,et al.Early assessment of lung cancer immunotherapy response via circulating tumor DNA[J].Clin Cancer Res,24(8):1872-1880. [19]Chaudhuri A,Chabon J,Lovejoy AF,et al.Early Detection of Molecular Residual Disease in ocalized Lung Cancer by Circulating Tumor DNA Profiling[J].Cancer Discov,2017,7(12):1394-1403. [20]Swanton C,Govindan R.Clinical Implications of Genomic Discoveries in Lung Cancer[J].N Engl J Med,2016,374(19):1864-1873. [21]Yong Li,Xudong Chen,Meixiao Zhan,Circulating Tumor DNA as a potential indicator of tumor load during interventional therapy of unresectable hepatocellular carcinoma[J].Journal of Clinical Oncology,2018,36(15-suppl):12036. [22]Remon J,Menis J,Hasan B,et al.The APPLE Trial:Feasibility and Activity of AZD9291 (Osimertinib)Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients[J].Clin Lung Cancer,2017,18(5):583-588.

相似文献/References:

[1]杨森果,毛大华,杨海松,等.E-cadherin与肿瘤侵袭、转移相关性研究进展[J].医学信息,2018,(03):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
 YANG Sen-guo,MAO Da-hua,YANG Hai-song,et al.Research Progress of the Correlation between E-cadherin and Tumor Invasion and Metastasis[J].Medical Information,2018,(19):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
[2]江立基,李先明.碳酸酐酶Ⅸ在肿瘤中的研究进展[J].医学信息,2018,(03):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
 JIANG Li-ji,LI Xian-ming.Research Progress of Carbonic Anhydrase IX in Cancer[J].Medical Information,2018,(19):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,(19):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]白 雪,邓 琦.血液系统肿瘤的细胞治疗研究进展[J].医学信息,2018,(10):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
 BAI Xue,DENG Qi.Advances in Cell Therapy for Blood System Tumor[J].Medical Information,2018,(19):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
[5]王 静,刘 梅,焦菊凤.知-信-行健康教育模式对PICC置管肿瘤 患者自我护理能力的影响[J].医学信息,2018,(11):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
 WANG Jing,LIU Mei,JIAO Ju-feng.Effect of Knowledge-belief-behavioral Health Education Model on the Self-care Ability of Patients with Cancer in PICC Catheterization[J].Medical Information,2018,(19):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
[6]史红娟,李群锋,赵 华,等.舒林酸抗肿瘤作用的研究进展[J].医学信息,2018,(12):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
 SHI Hong-juan,LI Qun-feng,ZHAO Hua,et al.Advances in Research on Anti-tumor Effect of Sulindac[J].Medical Information,2018,(19):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
[7]郑文灿,法艳梅,吕亚青,等.苦参碱抗肿瘤机制的分子生物学研究进展[J].医学信息,2018,(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
 ZHENG Wen-can,FA Yan-mei,LV Ya-qing,et al.Advances in Molecular Biology of Matrine Antitumor Mechanism[J].Medical Information,2018,(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
[8]缪继东.盐酸吗啡缓释片联合低剂量阿米替林治疗中重度癌性骨痛的疗效观察[J].医学信息,2018,(21):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
 MIAO Ji-dong.Effects of Morphine Hydrochloride Sustained-release Tablets Combined with Low Dose Amitriptyline in the Treatment of Moderate and Severe Cancer Bone Pain[J].Medical Information,2018,(19):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
[9]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,(02):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
 Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Medical Information,2019,(19):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
[10]郑晓凤,陈文凤,曾巧苗,等.肿瘤科医护人员营养知信行现状调查及影响因素分析[J].医学信息,2019,(12):129.[doi:10.3969/j.issn.1006-1959.2019.12.042]
 ZHENG Xiao-feng,CHEN Wen-feng,ZENG Qiao-miao,et al.Investigation on the Status Quo of Nutrition Knowledge and Knowledge of Medical Staff in Oncology Department and Analysis of Influencing Factors[J].Medical Information,2019,(19):129.[doi:10.3969/j.issn.1006-1959.2019.12.042]

更新日期/Last Update: 2019-10-01